Committee for Medicinal Products for Human Use (CHMP) has recommended approval of MSD’s KEYTRUDA for two gynaecological ...

Keytruda (pembrolizumab) is an immunotherapy drug used to treat many types of cancer. Your doctor will use imaging, blood tests, and other laboratory tests to monitor whether the drug is working.

Besides stomach cancer, the FDA also raised a similar concern for PD-1 drugs in first-line esophageal squamous cell carcinoma ...

Unlike Opdivo, Keytruda’s European licence stipulates ... Houson said routine NHS use – known as ‘baseline commissioning’ would be preferable, but said the CDF remained an option, and ...

Opdivo (nivolumab) and Merck's (NYSE:MRK) Keytruda (pembrolizumab), two highly popular checkpoint inhibitors used in the ...

MSD’s cancer immunotherapy, Keytruda, looks set to gain a lucrative first line lung cancer use in Europe, after regulators gave it the green light. Crucially, Keytruda (pembrolizumab ...

Japan’s MHLF approves Padcev with Keytruda for first-line treatment of radically unresectable urothelial carcinoma: Tokyo Wednesday, September 25, 2024, 11:00 Hrs [IST] Astellas ...

In 2021, the FDA blasted Merck for using a premature endpoint to pursue a Keytruda approval in early-stage triple-negative ...

Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...

In 2021, the FDA criticised MSD for relying on an early endpoint to seek approval for Keytruda in early-stage TNBC.

Despite positive KEYNOTE-811 results, Merck & Co’s position in this setting is not devoid of threats from other competitors.

Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the European Medicines Agency's ...